title: Neuroprotective activity of omega-3 fatty acids against epilepsy-induced hippocampal damage: Quantification with immunohistochemical for calcium-binding proteins.
abstract: To investigate whether n-3 polyunsaturated fatty acids (n-3 PUFAs) would promote different morphological changes in the hippocampal formation of rats with epilepsy, we performed an immunocytochemical study using parvalbumin (PV) and calretinin (CR) distribution as a marker. Animals subjected to the experimental model of epilepsy with a single dose of pilocarpine were randomly divided into the following groups: animals with epilepsy treated daily with vehicle (EV) and animals with epilepsy treated daily with 85 mg/kg n-3 PUFAs (EW). Control animals administered saline were also randomly divided into two other groups: animals treated daily with vehicle (CV) and animals treated daily with 85 mg/kg n-3 PUFAs (CW). A larger number of PV-positive neurons were observed in EW when compared with EV, CV, and CW. Similarly, there were significantly more CR-positive neurons in EW than in EV. These findings demonstrate that omega-3 fatty acids prevent status epilepticus-associated neuropathological changes in the hippocampal formation of rats with epilepsy.
authors.affiliation: Disciplina de Neurologia Experimental, Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, Brasil.
authors.forename: Danuza
authors.initials: D
authors.lastname: Ferrari
authors.forename: Roberta M
authors.initials: RM
authors.lastname: Cysneiros
authors.forename: Carla A
authors.initials: CA
authors.lastname: Scorza
authors.forename: Ricardo M
authors.initials: RM
authors.lastname: Arida
authors.forename: Esper A
authors.initials: EA
authors.lastname: Cavalheiro
authors.forename: Antonio-Carlos G
authors.initials: AC
authors.lastname: de Almeida
authors.forename: Fulvio A
authors.initials: FA
authors.lastname: Scorza
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001930:Brain Injuries / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D064032:Calbindin 2; D002452:Cell Count / Q000379:methods; D004195:Disease Models, Animal; D004827:Epilepsy / Q000139:chemically induced / Q000150:complications; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010320:Parvalbumins / Q000378:metabolism*; D010862:Pilocarpine; D051381:Rats; D017207:Rats, Sprague-Dawley; D064030:S100 Calcium Binding Protein G / Q000378:metabolism*; D012601:Scopolamine
chemical_list: C576512:Calb2 protein, rat; D064032:Calbindin 2; D015525:Fatty Acids, Omega-3; D018696:Neuroprotective Agents; D010320:Parvalbumins; D064030:S100 Calcium Binding Protein G; D010862:Pilocarpine; D012601:Scopolamine